Nathalie Jeandidier

Nathalie Jeandidier

Auto-generated profile, based on publicly available information

Nathalie Jeandidier

Service d’Endocrinologie — Diabète et Maladies Métaboliques — Hôpital Civil — CHRU — 67091 Strasbourg Cedex

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2016 in Nutrition & Metabolism
Verified
Journal Article
Open access
PDF file
ILIona Lozano
Iona Lozano
RWRemmelt Van der Werf
Remmelt Van der Werf
WBWilliam Bietiger
William Bietiger
ESElodie Seyfritz
Elodie Seyfritz
CPClaude Peronet
Claude Peronet
SDStéphanie Dal
Stéphanie Dal
As a result of the increased consumption of sugar-rich and fatty-products, and the increase in preference for such products, metabolic disorders are becoming more common at a younger age. Fructose is particularly used in prepared foods and carbonated beverages. We investigated the impact of regular consumption of fructose, in combination or not with fatty food, on the onset of metabolic syndrome and type 2 diabetes (T2D). We evaluated the metabolic, oxidative, and functional effects on the liver and blood vessels, both related to diabetes complications. High-fat diet (HFD), high-fructose beverages (HF) or both (HFHF) were compared to rats fed with normal diet (ND) for 8 months to induce T2D and its metabolic, oxidative, and functional complications. Metabolic control was determined by measuring body weight, fasting blood glucose, C-peptide, HOMA2-IR, leptin, and cholesterol; oxidative parameters were studied by lipid peroxidation and total antioxidant capacity in plasma and the use of ROS labelling on tissue. Histological analysis was performed on the liver and endothelial function was performed in main mesenteric artery using organ-baths. After 2 months, HFHF and HFD increased body weight, leptin, HOMA2-IR associated to steatosis, oxidative stress in plasma and tissues, whereas HF had only a transient increase of leptin and c-peptide. Only HFHF induced fasting hyperglycaemia after 6 months and persistent hyperinsulinaemia and fasting hyperglycaemia with complicated steatosis (inflammation and fibrosis) after 8 months. HFHF and HFD induced endothelial dysfunction at 8 months of diet. Six months, high fat and high carbohydrate induced T2D with widespread tissues effects. We demonstrated the role of oxidative stress in pathogenesis as well as in complications (hepatic and vascular), reinforcing interest in the use of antioxidants in the prevention and treatment of metabolic diseases, including T2D.

28 November 2014 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
NANathalie Auberval
Nathalie Auberval
SDStéphanie Dal
Stéphanie Dal
WBWilliam Bietiger
William Bietiger
MPMichel Pinget
Michel Pinget
NJNathalie Jeandidier
Nathalie Jeandidier
SSSeverine Sigrist
Severine Sigrist
Metabolic syndrome is associated with an increased risk of cardiovascular and hepatic complications. Oxidative stress in metabolic tissues has emerged as a universal feature of metabolic syndrome and its co-morbidities. We aimed to develop a rapidly and easily induced model of metabolic syndrome in rats to evaluate its impact on plasma and tissue oxidative stress.

23 May 2024 in Diabetologia
Verified
Journal Article
Open access
PDF file
GFGuy Fagherazzi
Guy Fagherazzi
GAGloria Aguayo
Gloria Aguayo
LZLu Zhang
Lu Zhang
HHHélène Hanaire
Hélène Hanaire
SPSylvie Picard
Sylvie Picard
JRJean-Pierre Riveline
Jean-Pierre Riveline
Aims/hypothesis: Our study aims to uncover glycaemic phenotype heterogeneity in type 1 diabetes. Methods: In the Study of the French-speaking Society of Type 1 Diabetes (SFDT1), we characterised glycaemic heterogeneity thanks to a set of complementary metrics: HbA1c, time in range (TIR), time below range (TBR), CV, Gold score and glycaemia risk index (GRI). Applying the Discriminative Dimensionality Reduction with Trees (DDRTree) algorithm, we created a phenotypic tree, i.e. a 2D visual mapping. We also carried out a clustering analysis for comparison. Results: We included 618 participants with type 1 diabetes (52.9% men, mean age 40.6 years [SD 14.1]). Our phenotypic tree identified seven glycaemic phenotypes. The 2D phenotypic tree comprised a main branch in the proximal region and glycaemic phenotypes in the distal areas. Dimension 1, the horizontal dimension, was positively associated with GRI (coefficient [95% CI]) (0.54 [0.52, 0.57]), HbA1c (0.39 [0.35, 0.42]), CV (0.24 [0.19, 0.28]) and TBR (0.11 [0.06, 0.15]), and negatively with TIR (−0.52 [−0.54, −0.49]). The vertical dimension was positively associated with TBR (0.41 [0.38, 0.44]), CV (0.40 [0.37, 0.43]), TIR (0.16 [0.12, 0.20]), Gold score (0.10 [0.06, 0.15]) and GRI (0.06 [0.02, 0.11]), and negatively with HbA1c (−0.21 [−0.25, −0.17]). Notably, socioeconomic factors, cardiovascular risk indicators, retinopathy and treatment strategy were significant determinants of glycaemic phenotype diversity. The phenotypic tree enabled more granularity than traditional clustering in revealing clinically relevant subgroups of people with type 1 diabetes. Conclusions/interpretation: Our study advances the current understanding of the complex glycaemic profile in people with type 1 diabetes and suggests that strategies based on isolated glycaemic metrics might not capture the complexity of the glycaemic phenotypes in real life. Relying on these phenotypes could improve patient stratification in type 1 diabetes care and personalise disease management. Graphical

1 January 2006 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
AAArnaud Agin
Arnaud Agin
NJNathalie Jeandidier
Nathalie Jeandidier
FGFrançoise Gasser
Françoise Gasser
DGDaniel Grucker
Daniel Grucker
RSRémy Sapin
Rémy Sapin
Clin Chem Lab Med 2006;44:1379–82.

1 January 2002 in Diabetes Care
Verified
Journal Article
Open access
PDF file
NJNathalie Jeandidier
Nathalie Jeandidier
SBSylvie Boullu
Sylvie Boullu
MBMarie-Sophie Busch-Brafin
Marie-Sophie Busch-Brafin
GCGerard Chabrier
Gerard Chabrier
RSRémy Sapin
Rémy Sapin
MPMichel Pinget
Michel Pinget
OBJECTIVE—To assess the antigenicity of the insulin Hoechst 21PH (Hoe21PH) using continuous subcutaneous insulin infusion (CSII) and to compare the antigenicity of this insulin when administered intraperitoneally or subcutaneously. RESEARCH DESIGN AND METHODS—Peritoneal administration of Hoe21PH (Hoechst-Roussel, Somerville, NJ) insulin using implantable devices (continuous peritoneal insulin infusion [CPII]) increases anti-insulin antibody (AIA) levels in type 1 diabetic patients. Intraperitoneal administration, addition of a stabilizer (polyethylene polypropylene glycol), or insulin modifications due to storage in the pump may be involved in this antigenicity. In this nonrandomized study, 24 type 1 diabetic patients were treated with either CSII (n = 11, group 1) or CPII (n = 13, group 2). AIA levels were measured by radioimmunoassay (RIA) or enzyme-linked immunosorbent assay (ELISA) before starting patients on Hoe21PH and again after 3 and 6 months. RESULTS—Patients were comparable in the two groups. AIA levels (RIA) remained stable (24.3 ± 8.5% [month 0] to 24.9 ± 8.5.5% [month 6]) in group 1 and increased (21.8 ± 6.7% [month 0] to 41.8 ± 6.9% [month 6]) in group 2 (P = 0.005, Wilcoxon’s rank-sum test). Using ELISA, AIA remained stable in the patients in group 1 (n = 9; 3.8 ± 0.8 units/ml [month 0] and 4.1 ± 1.0 units/ml [month 6]) and tended to increase in the patients in group 2 (n = 12; 4.1 ± 0.7 units/ml [month 0] to 17.5 ± 4.6 units/ml [month 6]) (P = 0.07). Comparison of the evolution of AIA formation between the two groups, using RIA at months 0, 3, and 6 showed a significant difference (analysis of variance, P = 0.009). CONCLUSIONS—No increase in AIA levels was demonstrated when Hoe21PH insulin was administered subcutaneously as assessed by two different assays. CPII is proven to be more antigenic than CSII, and this is not related to a specific antigenicity of Hoe21PH insulin. The intraperitoneal route of administration or insulin modifications due to insulin storage in implantable devices might explain this antigenicity.

23 October 2019 in GeroScience
Verified
Journal Article
Closed access
PDF file
TBThibault BAHOUGNE
Thibault BAHOUGNE
EAEleni Angelopoulou
Eleni Angelopoulou
NJNathalie Jeandidier
Nathalie Jeandidier
VSValérie Simonneaux
Valérie Simonneaux